Who is the Top Investor In BridgeBio Pharma Inc (BBIO)?

BridgeBio Pharma Inc (NASDAQ: BBIO) is -18.36% lower on its value in year-to-date trading and has touched a low of $10.57 and a high of $44.32 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BBIO stock was last observed hovering at around $33.77 in the last trading session, with the day’s loss setting it -0.81%.

Currently trading at $32.96, the stock is -9.30% and -8.88% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.04 million and changing -2.40% at the moment leaves the stock 23.16% off its SMA200. BBIO registered 179.09% gain for a year compared to 6-month gain of 4.07%. The firm has a 50-day simple moving average (SMA 50) of $734.59 and a 200-day simple moving average (SMA200) of -$12.92.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -17.04% loss in the last 1 month and extending the period to 3 months gives it a 12.15%, and is -1.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.14% over the week and 5.01% over the month.

BridgeBio Pharma Inc (BBIO) has around 396 employees, a market worth around $5.73B and $9.43M in sales. Profit margin for the company is -6498.14%. Distance from 52-week low is 211.83% and -25.63% from its 52-week high. The company has generated returns on investments over the last 12 months (-117.06%).

BridgeBio Pharma Inc quarterly earnings per share for the current quarter are estimated at -$0.91 with sales reaching $6.23M over the same period.The EPS is expected to shrink by -15.23% this year, but quarterly earnings will post -83.60% year-over-year. Quarterly sales are estimated to grow 233.20% in year-over-year returns.

318 institutions hold shares in BridgeBio Pharma Inc (BBIO), with institutional investors hold 100.99% of the company’s shares. The shares outstanding are 150.63M, and float is at 128.31M with Short Float at 12.56%. Institutions hold 95.18% of the Float.

The top institutional shareholder in the company is Kohlberg Kravis Roberts & Co. L.P. with over 31.06 million shares valued at $534.25 million. The investor’s holdings represent 19.12% of the BBIO Shares outstanding. As of Jun 29, 2023, the second largest holder is Viking Global Investors, L.P. with 26.62 million shares valued at $457.88 million to account for 16.38% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 11.68 million shares representing 7.19% and valued at over $200.98 million, while Blackrock Inc. holds 5.90% of the shares totaling 9.58 million with a market value of $164.81 million.

BridgeBio Pharma Inc (BBIO) Insider Activity

A total of 14 insider transactions have happened at BridgeBio Pharma Inc (BBIO) in the last six months, with sales accounting for 8 and purchases happening 6 times. The most recent transaction is an insider sale by Valantine Hannah, the company’s Director. SEC filings show that Valantine Hannah sold 2,915 shares of the company’s common stock on Jan 16 at a price of $37.97 per share for a total of $0.11 million. Following the sale, the insider now owns 1764.0 shares.

BridgeBio Pharma Inc disclosed in a document filed with the SEC on Dec 26 that MCCORMICK FRANK (Director) sold a total of 100,000 shares of the company’s common stock. The trade occurred on Dec 26 and was made at $42.06 per share for $4.21 million. Following the transaction, the insider now directly holds 0.63 million shares of the BBIO stock.

Still, SEC filings show that on Dec 18, Scott Randal W. (Director) disposed off 2,000 shares at an average price of $40.00 for $80000.0. The insider now directly holds 9,000 shares of BridgeBio Pharma Inc (BBIO).